249937-00-6

Basic information

• Product Name: METHYL 3-(2-MORPHOLIN-4-YLETHOXY)BENZOATE
• Synonyms: METHYL 3-(2-MORPHOLIN-4-YLETHOXY)BENZOATE;Methyl 3-(2-morpholin-4-ylethoxy)benzoate 97%
• CAS NO: 249937-00-6
• Molecular Formula: C₁₄H₁₉NO₄
• Molecular Weight: 265.3
• Mol File: 249937-00-6.mol

Chemical Properties

• Boiling Point: 396.9 °C at 760 mmHg
• Flash Point: 193.9 °C
• Appearance: /
• Density: 1.141 g/cm³
• Vapor Pressure: 1.65E-06mmHg at 25°C
• Refractive Index: 1.522
• CAS DataBase Reference: METHYL 3-(2-MORPHOLIN-4-YLETHOXY)BENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3-(2-MORPHOLIN-4-YLETHOXY)BENZOATE(249937-00-6)
• EPA Substance Registry System: METHYL 3-(2-MORPHOLIN-4-YLETHOXY)BENZOATE(249937-00-6)

Safety Data

• Hazardous Substances Data: 249937-00-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 3-(2-MORPHOLIN-4-YLETHOXY)BENZOATE is used as a pharmaceutical intermediate for the synthesis of various drug compounds, leveraging its chemical properties to contribute to the development of new medications.
Used in Research and Development:
In the pharmaceutical and medical industries, METHYL 3-(2-MORPHOLIN-4-YLETHOXY)BENZOATE is used as a research and development tool to explore its potential applications and to enhance the understanding of its properties and effects.
Used in Sedative and Analgesic Formulations:
METHYL 3-(2-MORPHOLIN-4-YLETHOXY)BENZOATE is used as a sedative and analgesic agent, capitalizing on its inherent properties to provide relief from pain and promote relaxation in medical treatments.

InChI:InChI=1/C14H19NO4/c1-17-14(16)12-3-2-4-13(11-12)19-10-7-15-5-8-18-9-6-15/h2-4,11H,5-10H2,1H3

Upstream product

• 19438-10-9 methyl 3-hydroxybenzoate 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 
• 3240-94-6 N-(2-chlorethyl)morpholine 

Downstream Products

• 219935-32-7 3-{[2-(4-morpholinyl)ethyl]oxy}benzoic acid 
• 331777-15-2 2-[3-(2-morpholin-4-ylethoxy)benzoyl]acetonitrile 

Relevant articles and documents

4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives

The present invention relates to compounds of the formula medicaments containing them and the use of these compounds as pharmaceutically active agents. The compounds exhibit activity as Raf kinase inhibitors and therefore may be useful for the treatment of diseases mediated by said kinases, especially as anticancer agents.

Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3- dihydroxypropoxy)phenyl]-methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 Map kinase

A novel class of highly selective inhibitors of p38 MAP kinase was discovered from high throughput screening. The synthesis and optimization of a series of 5-amino-N-phenyl-1H-pyrazol-4-yl-3-phenylmethanones is described. An X-ray crystal structure of this series bound in the ATP binding pocket of unphosphorylated p38a established the presence of a unique hydrogen bond between the exocyclic amine of the inhibitor and threonine 106 which likely contributes to the selectivity for p38. The crystallographic information was used to optimize the potency and physicochemical properties of the series. The incorporation of the 2,3-dihydroxypropoxy moiety on the pyrazole scaffold resulted in a compound with excellent drug-like properties including high oral bioavailability. These efforts identified 63 (RO3201195) as an orally bioavailable and highly selective inhibitor of p38 which was selected for advancement into Phase I clinical trials.